J. Whisenant

发表

Novel exon 2 α spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct α spectrin defects

N. Agarwal, J. Prchal, F. Lorenzo, 2013, Haematologica.

Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.

J. Moser, I. Garrido-Laguna, J. Whisenant, 2019, Journal of Clinical Oncology.

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy

S. Lloyd, R. Tao, C. Scaife, 2018, ESMO Open.

Regional therapy of liver metastases

A. Venook, J. Whisenant, 2004, Current treatment options in oncology.

Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process

M. Choti, J. Sicklick, M. Broder, 2020, Cancers.

Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series

D. Stenehjem, Sunil Sharma, I. Garrido-Laguna, 2018, Journal of Immunotherapy and Precision Oncology.

Synthetic helical peptide capping strategies.

K. Burgess, J. Whisenant, 2022, Chemical Society reviews.

Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps

K. Burgess, J. Whisenant, 2020, ACS medicinal chemistry letters.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

J. Berlin, T. Giordano, M. Heslin, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

A. Zhu, M. Borad, G. Abou-Alfa, 2019, Annals of Oncology.

Vulvar Recurrences After Intensity-modulated Radiation Therapy for Squamous Cell Carcinoma of the Anus

W. Sause, H. T. Kim, J. Whisenant, 2016, American journal of clinical oncology.

Discrepancies between tumor genomic profiling and germline genetic testing

S. Greenberg, I. Garrido-Laguna, J. Whisenant, 2022, ESMO open.

Comparison of updated Vitek Yeast Biochemical Card and API 20C yeast identification systems

K. Carroll, J. Whisenant, J. Fenn, 1994, Journal of clinical microbiology.

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

J. Yap, A. Welm, B. Welm, 2019, Nature Medicine.

Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.

I. Garrido-Laguna, J. Whisenant, P. Maeda, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

S. Choe, A. Zhu, M. Borad, 2021, JAMA oncology.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

A. Zhu, M. Borad, G. Abou-Alfa, 2020, The Lancet. Oncology.

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer

Sunil Sharma, K. Boucher, D. Stenehjem, 2018, Investigational New Drugs.

Anti-angiogenic strategies in gastrointestinal malignancies

J. Whisenant, Emily Bergstand, 2005, Current treatment options in oncology.

N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012

Sunil Sharma, Jian Ying, Kai Wang, 2015, Oncoscience.

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

J. Yap, A. Welm, B. Welm, 2019, Nature Medicine.

Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

S. Lloyd, R. Tao, D. Boothe, 2017, Cancer.

Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer

P. Das, S. Lloyd, R. Tao, 2017, Current Colorectal Cancer Reports.

Unconventional Secondary Structure Mimics: Ladder‐Rungs

K. Burgess, J. Whisenant, Chen-Ming Lin, 2020, Angewandte Chemie.

Unconventional Secondary Structure Mimics: Ladder-rungs.

K. Burgess, J. Whisenant, Chen-Ming Lin, 2020, Angewandte Chemie.

Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines

J. Berlin, T. Giordano, M. Heslin, 2018 .

Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.

M. Choti, J. Sicklick, M. Broder, 2017 .

Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

J. Yap, A. Welm, B. Welm, 2019, Nature Network Boston.

Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival

Ken R. Smith, N. Samadder, M. Hashibe, 2019, American journal of clinical oncology.

(OA44) Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival

N. Samadder, M. Hashibe, Jihye Park, 2018, International Journal of Radiation Oncology*Biology*Physics.

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

A. Zhu, M. Borad, G. Abou-Alfa, 2021 .

Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis

S. Lloyd, R. Tao, C. Scaife, 2017, Annals of Surgical Oncology.

Novel total synthesis of anserinone A and B

J. Whisenant, S. David, M. Blanco, 2017 .

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

Sunil Sharma, F. Janku, D. Hong, 2018 .

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

K. Boucher, J. Whisenant, J. Hawks, 2023, BMC Research Notes.

Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis

S. Lloyd, R. Tao, C. Scaife, 2017, Annals of Surgical Oncology.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

J. Berlin, T. Giordano, M. Heslin, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.